Bourel Dominique, Teillaud Jean-Luc
Département Recherche, Laboratoire Français du Fractionnement et des Biotechnologies, 3, av. des Tropiques, BP 305, Les Ulis, 91958 Courtaboeuf, France.
C R Biol. 2006 Apr;329(4):217-27. doi: 10.1016/j.crvi.2006.02.006. Epub 2006 Mar 29.
Engineering monoclonal antibodies, now widely used in the clinic, has made it possible to develop a new generation of antibodies with optimized functional properties. These antibodies should allow a significant improvement of the treatment of diseases where only few drugs are available, if any. However, the cost of treatments with monoclonal antibodies requires further improvements in production and purification technologies, and raises the question of generic antibodies. The present review summarizes some of the technological past and present challenges in the field.
工程单克隆抗体目前在临床上广泛应用，使得开发具有优化功能特性的新一代抗体成为可能。这些抗体有望显著改善那些可用药物极少（甚至没有）的疾病的治疗效果。然而，单克隆抗体治疗的成本要求在生产和纯化技术方面进一步改进，并引发了通用抗体的问题。本综述总结了该领域过去和现在的一些技术挑战。
